Publications (102) VICTOR MANGAS SANJUAN publications

2024

  1. Bioequivalence risk assessment of oral formulations containing racemic ibuprofen through a chiral physiologically based pharmacokinetic model of ibuprofen enantiomers

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 199

  2. Impact of Time on Parameters for Assessing the Microstructure Equivalence of Topical Products: Diclofenac 1% Emulsion as a Case Study

    Pharmaceutics, Vol. 16, Núm. 6

  3. Integrating Mechanistic and Toxicokinetic Information in Predictive Models of Cholestasis

    Journal of Chemical Information and Modeling, Vol. 64, Núm. 7, pp. 2775-2788

  4. Metodologías activas centradas en el paciente para mejorar el aprendizaje en Farmacia Clínica y Atención Farmacéutica, una asignatura esencial para iniciar en la práctica profesional

    Pharmaceutical care España, Vol. 26, Núm. 2, pp. 325-325

  5. New insights into the role of VKORC1 polymorphisms for optimal warfarin dose selection in Caribbean Hispanic patients through an external validation of a population PK/PD model

    Biomedicine and Pharmacotherapy, Vol. 170

  6. Phys-DAT: A physiologically-based pharmacokinetic model for unraveling the dissolution, transit and absorption processes using PhysPK®

    Computer Methods and Programs in Biomedicine, Vol. 243

  7. Population Pharmacokinetic–Pharmacodynamic Analysis of a Reserpine-Induced Myalgia Model in Rats

    Pharmaceutics, Vol. 16, Núm. 8

  8. Towards precision medicine of long-acting aripiprazole through population pharmacokinetic modelling

    Psychiatry Research, Vol. 333

2023

  1. Alternative Pharmacokinetic Metrics in Single-Dose Studies to Ensure Bioequivalence of Prolonged-Release Products at Steady State—A Case Study

    Pharmaceutics, Vol. 15, Núm. 2

  2. Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies

    British Journal of Clinical Pharmacology, Vol. 89, Núm. 9, pp. 2691-2702

  3. Characterization of the interplay between different biological factors driving tumor growth dynamics in the absence of treatment.

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  4. Commonly used methods for dissolution profile comparison

    Time-Proof Perspectives on Bioequivalence (Nova Science Publishers, Inc.), pp. 297-322

  5. Conceptos y aplicaciones de los parámetros farmacocinéticos: Una guía para el salón de clases

    Journal of Pharmacy and Pharmacognosy Research, Vol. 11, Núm. 1, pp. 160-178

  6. Correction: A Review of Population Pharmacokinetic Analyses of Linezolid (Clinical Pharmacokinetics, (2022), 61, 6, (789-817), 10.1007/s40262-022-01125-2)

    Clinical Pharmacokinetics

  7. Desarrollo y validación de un modelo farmacocinético fisiológico para las formas ácidas y lactonizadas de atorvastatina y sus dos metabolitos

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  8. Editorial: Innovative pharmacometric approaches to inform drug development and clinical use

    Frontiers in Pharmacology

  9. Introducción a la famacocinética

    Fundamentos de farmacología básica y clínica (Editorial Médica Panamericana), pp. 169-179

  10. Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: The interplay between cancer cells and components of tumor microenvironment

    PLoS Computational Biology, Vol. 19, Núm. 10

  11. Regulatory Requirements for the Development of Second-Entry Semisolid Topical Products in the European Union

    Pharmaceutics, Vol. 15, Núm. 2

  12. Usage of model combination in computational toxicology

    Toxicology Letters, Vol. 389, pp. 34-44